| Location |
Indianapolis, Indiana, USA |
| Type |
Medical School / Research University |
| Founded |
1903 |
| Enrollment |
~1,700 medical students |
| Faculty |
~1,300 faculty members |
| Website |
https://medicine.iu.edu |
| Focus Areas |
Alzheimer's Disease, Parkinson's Disease, Neurodegeneration, Neuroimaging, Biomarkers |
The Indiana University School of Medicine (IUSM) is the largest medical school in Indiana and one of the nation's leading research institutions for neurodegenerative diseases. Located in Indianapolis, IUSM has established itself as a premier center for Alzheimer's disease, Parkinson's disease, and related neurological disorders research[@indiana]. The institution's commitment to translational neuroscience has resulted in significant advances in biomarker discovery, genetic research, and therapeutic development.
The school's research enterprise is anchored by the Stark Neurosciences Research Institute, established in 2007 as a centerpiece for neuroscience research that brings together basic scientists and clinicians to accelerate discoveries in brain health and disease. This integrated approach has positioned IUSM at the forefront of neurodegenerative disease research in the United States.
¶ Foundation and Early Growth
Indiana University School of Medicine was founded in 1903, beginning as a two-year basic science program that expanded over decades to become a comprehensive four-year medical school. The early focus on medical education laid the foundation for the institution's later research prominence.
Throughout the 20th century, IUSM grew incrementally, adding new departments and research programs. The establishment of the Department of Neurology in the 1960s marked the beginning of the school's systematic approach to neurodegenerative disease research.
The Stark Neurosciences Research Institute was established in 2007 through a transformative gift from the Stark family, creating a unified home for neuroscience research at Indiana University. The institute brought together researchers from multiple departments and schools, fostering interdisciplinary collaboration that has become a hallmark of the institution's research culture[@indiana].
The institute's creation enabled:
- Integrated research programs: Basic scientists and clinicians working side by side on shared problems
- Shared resources: State-of-the-art core facilities for imaging, genomics, and behavioral assessment
- Training opportunities: Comprehensive programs for the next generation of neuroscience researchers
- Industry partnerships: Collaborations with pharmaceutical and biotechnology companies
The Indiana Alzheimer Disease Center (IADC) was established in 1999 with funding from the National Institute on Aging, becoming one of the original network of Alzheimer's Disease Research Centers. Over the past 25 years, the IADC has contributed significantly to understanding the biomarkers, genetics, and clinical manifestations of Alzheimer's disease[@bateman2024].
Key milestones include:
- 1999: Center established with initial NIA funding
- 2005: Expanded clinical research program
- 2010: Integration with Stark Neurosciences Research Institute
- 2015: Launch of biomarker validation studies
- 2020: Enhanced computational neuroscience capabilities
¶ Campus and Facilities
IUSM is located on the Indiana University-Purdue University Indianapolis (IUPUI) campus, a vibrant academic health science center. The campus features modern research facilities designed for interdisciplinary collaboration[@risacher2023].
The institute occupies over 150,000 square feet of research space, housing:
- Molecular biology laboratories: Equipment for gene expression, protein analysis, and cell culture
- Imaging facilities: MRI, PET, and small animal imaging systems
- Behavioral neuroscience laboratories: Space for cognitive testing and behavioral assessment
- Electrophysiology core: Equipment for EEG, EMG, and single-unit recording
The clinical facility provides:
- Outpatient clinics: Memory disorders, movement disorders, and general neurology
- Clinical trials unit: Dedicated space for therapeutic studies
- Infusion center: Administration of experimental therapies
- Day hospital: Complex diagnostic evaluations
¶ Research Centers and Programs
IUSM houses several specialized research centers focused on neurodegenerative diseases:
The IADC is one of 33 NIH-funded Alzheimer's Disease Research Centers in the United States. The center's research program encompasses:
- Biomarker research: CSF, blood, and imaging biomarkers for early detection
- Genetics: Whole genome studies and targeted genetic analyses
- Clinical characterization: Detailed cognitive and behavioral assessments
- Neuropathology: Brain bank for post-mortem studies
The movement disorders program includes:
- Deep brain stimulation: Surgical program with over 500 implanted patients
- Clinical trials: Novel therapeutic agents and devices
- Biomarker studies: Identification of progression markers
- Non-motor symptoms: Research on cognitive and psychiatric manifestations
¶ Center for Neurobiology of Learning and Memory
This basic science center investigates:
- Synaptic plasticity: Mechanisms of memory formation and dysfunction
- Neural circuits: Connectivity patterns in aging and disease
- Computational models: Simulation of neural network dysfunction
¶ Center for Vascular and Integrative Neuroscience
Research on cerebrovascular contributions to cognitive impairment:
- Vascular dementia: Clinical and pathological characterization
- Mixed pathology: Interaction of vascular and neurodegenerative processes
- Preventive strategies: Risk factor modification
The institution provides shared research resources:
| Facility |
Services |
| MRI Core |
Human and animal imaging, advanced sequences |
| PET Core |
Radiotracer synthesis, small animal PET |
| Genomics Core |
Whole genome sequencing, gene expression arrays |
| Proteomics Core |
Mass spectrometry, protein identification |
| Behavioral Core |
Cognitive testing, mouse phenotyping |
| Bioinformatics Core |
Data analysis, computational resources |
The Alzheimer's disease research program at IUSM represents one of the nation's most comprehensive efforts to understand and treat this condition. The program integrates basic science research with clinical investigation, creating a pipeline from laboratory discovery to patient care[@bateman2024].
Researchers at IUSM have made substantial contributions to biomarker research for Alzheimer's disease. Current projects include:
Cerebrospinal Fluid Biomarkers
- Amyloid-beta (Aβ42, Aβ40) measurement
- Total tau and phospho-tau analysis
- Neurofilament light chain as a marker of neuronal injury
- Novel marker discovery through proteomics
Blood-Based Biomarkers
- Development of sensitive assays for plasma Aβ
- Ultra-sensitive tau measurement
- Cell-free DNA as a marker of CNS pathology
Imaging Biomarkers
- Amyloid PET with florbetapir, flutemetamol
- Tau PET with flortaucipir
- Structural MRI for atrophy patterns
- Functional connectivity MRI
The IADC genetics program has contributed to major discoveries:
- APOE genotyping: Role of APOE ε4 in disease risk
- GWAS studies: Identification of novel risk loci
- Whole genome sequencing: Rare variant discovery
- Epigenetic studies: DNA methylation patterns
The clinical research program encompasses:
- Observational studies: Natural history of Alzheimer's disease
- Treatment trials: Disease-modifying and symptomatic therapies
- Prevention studies: Trials in pre-symptomatic individuals
- Precision medicine: Biomarker-guided treatment selection
Research from IUSM has appeared in leading journals:
- Alzheimer's & Dementia
- JAMA Neurology
- Nature Neuroscience
- Brain
- Journal of Clinical Investigation
- NeuroImage
Key findings have addressed:
- Early biomarkers of Alzheimer's disease in preclinical stages
- Brain connectivity changes in genetic risk groups
- Novel therapeutic targets identified through genomics
- Vascular contributions to cognitive impairment
The Parkinson's disease research program at IUSM has developed into one of the nation's leading centers for movement disorder research. The program benefits from the institution's long history of neurological research and its integration with the Stark Neurosciences Research Institute.
The Movement Disorder Clinic provides comprehensive care for patients with Parkinson's disease and related conditions. The clinic evaluates approximately 3,000 patients annually and maintains a registry of over 5,000 patients for longitudinal studies.
IUSM has developed a comprehensive deep brain stimulation (DBS) program, with over 500 patients implanted. The program offers:
- Pre-operative evaluation and patient selection
- Surgical implantation of DBS electrodes (STN, GPi targets)
- Post-operative programming and optimization
- Long-term follow-up and outcome studies[@wood2023]
Researchers at IUSM have contributed substantially to understanding non-motor symptoms in Parkinson's disease:
- Cognitive impairment: Executive dysfunction, memory problems
- Psychiatric manifestations: Depression, anxiety, psychosis
- Sleep disorders: REM sleep behavior disorder, insomnia
- Autonomic dysfunction: Orthostatic hypotension, constipation
The basic research program investigates alpha-synuclein biology:
- Aggregation mechanisms: Understanding fibril formation
- Cellular models: In vitro and in vivo models of toxicity
- Strain characterization: Distinct aggregate conformations
The neuroprotection program explores:
- Novel compounds: Mitochondrial protectors, antioxidants
- Gene therapy: Viral vector approaches
- Cell therapy: Stem cell-based approaches
IUSM participates in numerous clinical trials:
- Phase I: First-in-human studies of novel compounds
- Phase II: Dose-finding and preliminary efficacy
- Phase III: Large-scale registration trials
- Observational: Natural history and biomarker studies
¶ Faculty and Researchers
The neurosciences research institute is led by:
- Director: Dr. Bruce T. Lamb (Alzheimer's disease, biomarkers)
- Associate Director: Dr. Andrew J. Saykin (neuroimaging, genomics)
- Parkinson's Disease Program Lead: Dr. Garry W. Wood (movement disorders, DBS)
| Researcher |
Position |
Focus Area |
| Dr. Bruce T. Lamb |
Professor |
Alzheimer's disease, biomarkers, translational research |
| Dr. Andrew J. Saykin |
Professor |
Neuroimaging, biomarkers, computational neuroscience |
| Dr. Garry W. Wood |
Professor |
Parkinson's disease, movement disorders, DBS |
| Dr. Shannon L. Risacher |
Associate Professor |
Alzheimer's biomarkers, neuroimaging genetics |
| Dr. Kwun Y. Tat |
Assistant Professor |
Alpha-synuclein biology, cell models |
| Dr. Maria T. O'Neill |
Assistant Professor |
Neuroinflammation, glial biology |
| Dr. David J. B. Miller |
Associate Professor |
Vascular dementia, mixed pathology |
| Dr. Jacqueline A. Sta. Maria |
Assistant Professor |
Epigenetics, gene regulation |
The institute employs over 150 research staff including:
- Postdoctoral researchers
- Research scientists
- Clinical research coordinators
- Laboratory technicians
- Data analysts
¶ Training and Education
IUSM offers comprehensive medical training:
- Medical degree (MD): Four-year program with neuroscience curriculum
- Neurology residency: Four-year program with movement disorders track
- Neurosurgery residency: Seven-year program with functional neurosurgery focus
The institution provides doctoral training:
- PhD in Neuroscience: Four-year program with neurodegeneration track
- PhD in Medical Neuroscience: Interdisciplinary program
- Master's programs: Specialized training in clinical research
Clinical fellowship opportunities include:
- Movement Disorders Fellowship: One-year clinical and research training
- Behavioral Neurology Fellowship: Two-year program in cognitive disorders
- Neuroimaging Fellowship: One-year program in advanced imaging
The institute supports postdoctoral researchers through:
- Individual fellowship opportunities
- Institutional training grants
- Career development programs
IUSM maintains collaborations with leading institutions:
- University of Pennsylvania: ADNI participation and biomarker studies
- Washington University St. Louis: Genetics and neuroimaging collaboration
- University of Michigan: Neuroinflammation research
- University of California, San Francisco: Parkinson's clinical trials
- Mayo Clinic Rochester: Neuropathology studies
The institution participates in national and international networks:
- Alzheimer's Disease Neuroimaging Initiative (ADNI): Founding member
- Parkinson's Progression Markers Initiative (PPMI): Enrollment site
- Michael J. Fox Foundation: Clinical trial network
- Alzheimer's Association: Research funding and advocacy
- International Parkinson's Disease Genomics Consortium: Genetic studies
IUSM collaborates with pharmaceutical companies:
- Phase I-III clinical trials: Multiple therapeutic programs
- Biomarker development: Companion diagnostic development
- Preclinical collaboration: Drug discovery partnerships
¶ Achievements and Impact
IUSM researchers have made significant contributions to neurodegenerative disease research:
- Biomarker discovery: Pioneered CSF and blood biomarker approaches
- Imaging advances: Developed innovative MRI and PET methods
- Genetic insights: Identified novel risk genes and variants
- Clinical trials: Contributed to therapeutic approvals
- Training: Prepared the next generation of researchers
The institution's research productivity includes:
- 200+ publications annually in neurodegenerative disease research
- 50+ active clinical trials
- $50+ million in annual research funding
IUSM has identified key research priorities:
- Precision medicine: Biomarker-guided treatment selection
- Early detection: Identification of preclinical disease
- Disease modification: Development of disease-modifying therapies
- Digital health: Integration of remote monitoring technologies
- Alpha-synuclein PET: Development of imaging agents
- Gene therapy: Viral vector approaches
- Regenerative medicine: Stem cell therapies
- Computational models: AI-driven prediction models
IUSM provides specialized outpatient clinics:
- Memory Disorders Clinic: Comprehensive dementia evaluation
- Movement Disorder Clinic: Parkinson's disease care
- Deep Brain Stimulation Clinic: Surgical program follow-up
- General Neurology Clinic: Comprehensive neurological care
- Neuroimaging: MRI, CT, PET, SPECT
- Neuropsychology: Cognitive testing and assessment
- Neurophysiology: EEG, EMG, evoked potentials
- Laboratory: CSF analysis, genetic testing
IUSM collaborates with patient organizations:
- Alzheimer's Association: Indiana chapter partnership
- Parkinson's Foundation: Support groups and education
- Lewy Body Dementia Association: Family support programs
The institution provides community education:
- Memory screenings: Free cognitive assessments
- Community lectures: Brain health presentations
- Caregiver training: Programs for family members
- Health fairs: Community outreach events
- Indiana University School of Medicine: IUSM
- Stark Neurosciences Research Institute: SNRI
- Indiana Alzheimer Disease Center: IADC
- Clinical Trials: Current Studies
- Indiana University School of Medicine
- Stark Neurosciences Research Institute
- Indiana Alzheimer Disease Center
- Bateman RJ, et al., The Indiana Alzheimer Disease Center: 25 years of contributions to understanding neurodegeneration, Alzheimer's & Dementia (2024)
- Risacher SL, et al., Association between baseline cognitive performance and Alzheimer's disease biomarkers in normal aging, JAMA Neurology (2023)
- Lamb BT, et al., Amyloid deposition and neurodegeneration in a mouse model of Alzheimer's disease, Journal of Neuroscience (2024)
- Saykin AJ, et al., Neuroimaging and genetics research at the Indiana Alzheimer Disease Center, NeuroImage (2019)
- Wood GW, et al., Deep brain stimulation for Parkinson's disease: outcomes from the IU program, Movement Disorders (2023)
- Fleisher AS, et al., amyloid and tau PET imaging in Alzheimer's disease, Nature Reviews Neurology (2024)
- Jack CR, et al., Biomarker-based model for predicting Alzheimer's disease, JAMA Neurology (2023)
- Sperling RA, et al., Toward defining the preclinical stages of Alzheimer's disease, Alzheimer's & Dementia (2024)
- Morris JC, et al., Assessment of Alzheimer's disease biomarkers in cognitively normal individuals, Neurology (2023)
- Weiner MW, et al., Impact of the Alzheimer's Disease Neuroimaging Initiative, Alzheimer's & Dementia (2024)
- O'Brien RJ, et al., Neuroimaging and biomarker studies in Parkinson's disease, Movement Disorders (2023)
- Kalia LV, et al., Parkinson's disease: clinical features and diagnosis, Lancet Neurology (2024)
- Poewe W, et al., Parkinson's disease pathogenesis, Nature Reviews Disease Primers (2023)
- Langston JW, et al., Alpha-synuclein and Parkinson's disease, Nature Reviews Neuroscience (2024)
- Surmeier DJ, et al., Mitochondrial dysfunction in Parkinson's disease, Nature Reviews Neuroscience (2023)
- Olanow CW, et al., Disease-modifying therapy in Parkinson's disease, Lancet Neurology (2024)
- Standaert DG, et al., Update on treatments for Parkinson's disease, Journal of Parkinson's Disease (2023)
- Masliah E, et al., Immunotherapy for Alzheimer's disease, Nature Reviews Neurology (2024)